EGFR and cancer: Taken together, this data suggests that coexisting subpopulations of cancer cells within the same tumor have different levels of sensitivity to targeted inhibitors even in the absence of genomic alterations (e.g., c-Met amplification) known to drive resistance to anti-EGFR treatment.